Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis

Kent, Peter D.; Davis, John M.; Davis, Mark D.P.; Matteson, Eric L.

doi:10.1002/art.10348

Cited by 36 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bullous skin lesions due to anti-TNF-α drugs are not very common as a clinical picture. In the literature, only bullous pemphigoid due to infliximab treatment has been described (9). Adalimumabinduced pemphigoid cases have not been previously reported.…”

Section: Discussionmentioning

confidence: 99%

A Case with Anti TNF- α Induced Bullous Pemhigoid

2010

View full text Add to dashboard Cite

ÖzetOtoimmün inflamatuvar hastalıkların etiyopatojenezinde TNFα'nın önemli rolü olduğu ve tedavide anti-TNF-α ilaçların yıllardan beri kullanıldığı bilinmektedir. Bununla birlikte bu ilaçların kullanımı sırasında farklı otoimmün hastalıkların ortaya çıkması gibi istenmeyen sonuçlarla karşılaşılabilmektedir. Bu yazıda romatoid artrit tanısıyla adalimumab kullandığı dönemde büllöz pemfigoid tablosu gelişen bir kadın hasta anlatıldı ve tartışıldı. ( Abst ractTumor necrosis factor-alpha (TNF-α) plays a crucial role in the development of autoimmune diseases, and anti-TNF-α agents are used in the treatment of this group of diseases. However, some adverse events such as various autoimmune diseases can occur with use of these agents. In this report, we present a female case who was diagnosed as bullous pemphigoid while receiving adalimumab for rheumatoid arthritis. (Turk J Rheumatol 2010; 25: 214-6)

show abstract

Section: Discussionmentioning

confidence: 99%

A Case with Anti TNF- α Induced Bullous Pemhigoid

2010

View full text Add to dashboard Cite

show abstract

“…Reported cutaneous side effects include rash, edema, urticaria, lupus-like illness, and bullous skin lesions. 1 To our knowledge, we report the first case of multiple squamous cell carcinomas and keratoacanthomas in a patient treated with infliximab for rheumatoid arthritis.…”

mentioning

confidence: 83%

Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

Esser

Abril

Fayne

et al. 2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…The close temporal relationship between the observed eruption and the infliximab perfusion is highly suggestive that these lesions are drug induced. They regressed completely after systemic steroid therapy [27]. …”

Section: Tnf-α Metabolic Pathway: Infliximab Etanercept and Adalimumabmentioning

confidence: 99%

Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature

Thielen¹,

Kuenzli²,

Saurat³

2005

Dermatology

View full text Add to dashboard Cite

The use of biological agents is expanding worldwide as a new treatment alternative for chronic inflammatory diseases including more recently skin diseases, especially psoriasis. Although frequently observed, the knowledge about acute and chronic dermatological adverse events is limited, and potential pathogenic mechanisms still have to be identified. Exact diagnosis is required considering that dermatological adverse events raise a decisional challenge about potential treatment discontinuation. The object of this publication is to present an overview of the dermatological adverse events of these new treatment alternatives.

show abstract

Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis

Cited by 36 publications

References 6 publications

A Case with Anti TNF- α Induced Bullous Pemhigoid

A Case with Anti TNF- α Induced Bullous Pemhigoid

Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab

Cutaneous Adverse Events of Biological Therapy for Psoriasis: Review of the Literature

Contact Info

Product

Resources

About